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Abstract: The Marfan syndrome is a heritable disorder of the connective tissue which affects 
the cardiovascular, ocular, and skeletal system. The cardiovascular manifestation with aortic 
root dilatation, aortic valve regurgitation, and aortic dissection has a prevalence of 60% to 90% 
and determines the premature death of these patients. Thirty-four percent of the patients with 
Marfan syndrome will have serious cardiovascular complications requiring surgery in the ﬁ  rst 
10 years after diagnosis. Before aortic surgery became available, the majority of the patients 
died by the age of 32 years. Introduction in the aortic surgery techniques caused an increase 
of the 10 year survival rate up to 97%. The purpose of this article is to give an overview about 
the feasibility and outcome of stent-graft placement in the descending thoracic aorta in Marfan 
patients with previous aortic surgery.
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Marfan disease
Marfan syndrome is a heritable disorder of the connective tissue with an autosomal-
dominant transmission and pleiotropic manifestations involving the ophthalmologic, 
musculoskeletal and cardiovascular systems (Pyeritz and McKusick 1979; Fattori et al 
1999). It is a relatively frequent manifestation of the most common genetic disorders, 
estimated to affect 1 in 6,000 to 10,000 people. The exact prevalence is unknown, but 
1 patient who satisﬁ  es strict diagnostic criteria is found per 10,000 patients, with no 
known gender or ethnic predilection.
Both medical and surgical concepts play an integrated role in the therapeutic 
management of cardiovascular manifestations of the Marfan syndrome and related 
disorders. Because of cardiovascular involvement, especially aortic dilation with 
subsequent dissection or rupture, Marfan syndrome is associated with signiﬁ  cant 
morbidity and mortality. The ﬁ  rst line therapeutic option for aortic pathologies in 
Marfan patients is the surgical reconstruction. Because Marfan syndrome is a disease 
of the entire aorta, there needs a close follow-up.
This article focuses on the cardiovascular aspects of Marfan syndrome and discusses 
the recent data on the ﬁ  eld of endovascular stent-graft placement in Marfan patients 
with previous aortic surgery.
Cardiovascular manifestations
The average life expectancy of untreated patients with Marfan syndrome is 32 years 
(Murdoch et al 1972). In  90% of cases in which a cause of death was identiﬁ  able, 
the cardiovascular system was involved, and the most common cause of death was 
aortic dissection or aortic rupture (Murdoch et al 1972). The cardiovascular mani-
festations, ﬁ  rst described in 1943, are clinically apparent in 40% to 60% of patients 
with Marfan syndrome. Moreover 34% of patients with Marfan syndrome will have Vascular Health and Risk Management 2008:4(1) 60
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serious cardiovascular complications requiring major cardiac 
surgery in the ﬁ  rst 10 years after diagnosis (Groenik et al 
1999). A common factor of all phenotypic forms of aortic 
wall disease is the dedifferentiation of vascular smooth 
muscle cells not only with classic aneurysm formation, but 
also from enhanced elastolysis of aortic wall components. 
In addition, mitral valve prolapse is the most prevalent val-
vular abnormality, affecting 35% to 100% of patients (Van 
Karnebeek et al 2001). Less commonly reported abnormali-
ties are tricuspid valve prolapse and dilatation of the main 
pulmonary artery. Thus, for approximately 2 decades, it 
has become clear that only the successful management of 
cardiovascular manifestations of the Marfan syndrome is 
likely to increase individual life expectancy. Fortunately, 
both medical and surgical therapies have proven capable of 
achieving this goal (Svennson et al 1989; Smith et al 1994; 
Antmann 1994).
Considering the limitations of physical examination, to 
recognize cardiovascular abnormalities in Marfan syndrome, 
echocardiography, computed tomography (CT) scanning, or 
magnetic resonance imaging (MRI) play an important role 
in the diagnostic work-up. The most frequent cardiovascular 
manifestations include aortic root dilation and aortic dissec-
tion. Aortic dissection or rupture and aortic regurgitation 
most often lead to death. The ascending aorta, aortic valve, 
and mitral valve can be evaluated by the 2-dimensional 
echocardiography and color Doppler interrogation in the 
parasternal long-axis orientation, and measurements can be 
obtained with the help of M-mode echocardiography. There 
are, however, patients with severe pectus abnormalities in 
whom a technically acceptable surface echocardiogram is 
impossible, and even transesophageal echocardiography 
(TEE) may be inadequate. MRI is an excellent alternative for 
these patients, as well as for pregnant patients in whom echo-
cardiography is sometimes difﬁ  cult (Schaeter et al 1987).
Aortic root involvement
Aortic abnormalities are found in 60% to 90% of patients with 
Marfan syndrome (Brown et al 1975; Devereux and Roman 
1999). The aortic root involvement is the classic feature 
with a greater prevalence in males than in females (Brown 
et al 1975). The sinuses of Valsalva are usually dilated at 
birth and were abnormal throughout life in proportion to 
body surface area with a variable rate of progression during 
adolescence (Gova et al 1990; Reed et al 1993). Echocardio-
graphic criteria for aortic root dilation as proposed by Brown 
and colleagues (1990) include a) width index of the aorta
 22 mm/m2; b) actual measurement of an aortic diameter 
 40 mm; and c) left atrial to aortic diameter ratio  0.7. Aortic 
diameter should be measured at the sinuses of Valsalva and 
related to normal values based on age and body surface area 
(Roman et al 1989). Aortic dilatation may be limited to the 
sinus of Valsalva or may involve the proximal and mid 
ascending aorta and increases at a variable rate. Hwa and 
colleagues (1993) reported an increase in 42% of Marfan 
patients by 1.9 mm yearly. The severity of aortic dilatation is 
related to the degree of aortic dilatation and to the length of 
the dilated segment. Generalized aortic dilatation in patients 
with Marfan syndrome is a marker for increased risk of sub-
sequent aortic complications (Roman et al 1993). Dilatation 
of the aorta is accompanied in 15% to 44% by aortic regurgi-
tation (Roman et al 1993). A myxomatous aortic valve may 
also contribute to aortic regurgitation (Roberts and Honig 
1985). Conventionally, regurgitation results from stretching 
of the commissures at the sino-tubular junction; therefore, at 
least a moderate degree of root dilation is necessary before 
a valvular leakage is present (Roberts and Honig 1985). For 
example, aortic regurgitation is uncommon in an adult with 
a maximum root dimension of 45 to 50 mm, but it is always 
present when the dimension is  60 mm (von Kodolitsch 
et al 1998a); cusp fenestrations or dissection can cause aortic 
regurgitation regardless of aortic dimension.
Aortic dissection
The prevalence of Marfan syndrome among patients with aor-
tic dissection is unclear but recent data from the International 
Registry of Aortic Dissection (IRAD) reported that 5% of the 
1049 patients had this disorder (Januzzi et al 2004) (Table 1). 
In other surveys the rate ranges between 3.2% and 5.8% (von 
Kodolitsch et al 2000; Mehta et al 2002). Aortic dissection 
generally occurs in the presence of an enlarged aortic root 
( 40 mm) and is associated with a family history of dissec-
tion. Aortic dilatation and dissection are mainly observed 
on the proximal part of the ascending aorta, just above the 
coronary ostia, which is submitted to maximal hemodynamic 
stress and is the richest in elastic ﬁ  bers as well as in ﬁ  brillin 
which may contribute to the pathogenesis of aortic dissec-
tion. The association between increased aneurysm diameter 
and the risk for dissection or rupture is clearly established 
so that an aneurysm size  6 cm cause a 4-fold increase in 
the cumulative risk (Davies et al 2002). However, 20% of 
dissections occur in patients with a normal aortic root size 
(<40 mm). Less than 20% of acute dissections in patients 
with Marfan syndrome are type B lesions; these usually 
arise distal to the left subclavian artery in an often undilated 
descending thoracic aorta (Hagan et al 2000). Moreover Vascular Health and Risk Management 2008:4(1) 61
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pregnancy in patients with Marfan syndrome is associated 
with an increased risk of aortic dissection, especially dur-
ing the third trimester, birth and the ﬁ  rst month post partum 
(Pyeritz 1981).
Type A dissection is the leading cause of death in Marfan 
syndrome, most frequently through retrograde extension into 
the pericardium with resulting lethal tamponade (Murdoch 
et al 1972). Acute dissection may be accompanied by all of 
the classic signs and symptoms, or it may be clinically silent. 
Some patients, however, feel that something is suddenly and 
deﬁ  nitely wrong and hurry to the emergency room where 
they are often misdiagnosed. Close inspection of the medical 
records of many such cases reveals that a life-threatening 
condition should have been suspected, either from the symp-
toms and signs or simply because the patient was known to 
have Marfan syndrome. The recommendations regarding 
timing of surgical repair have been determined, in part, by 
an appreciation of the risk of dissection. It has become clear 
recently that this risk is not the same for all aortas at a given 
diameter (Roberts and Honig 1985). A comparison between 
patients who sustained dissection, patients who underwent 
prophylactic repair of the aorta, and patients awaiting such 
surgery revealed that a family history of dissection is useful 
for stratiﬁ  cation (Pyeritz 1991).
Indication for surgery
Aortic dissection and rupture are the leading causes of mor-
bidity and mortality in Marfan syndrome, and prophylactic 
surgery is recommended to prevent this complication. The 
indication for prophylactic aortic surgery is been predicated 
on aortic size and recommended when the diameter reaches 
5.0 cm (Smith et al 1994; Davies et al 2002) or the diameter 
reaches twice of the adjacent segments (Svennson et al 1989; 
Smith et al 1994). Factors that promptly wants the recommen-
dation for surgery when the aorta is <5.0 cm include rapidly 
growth of the aortic diameter (5%/ year) (Antmann 1994), a 
family history of premature aortic dissection and the presence 
of greater than mild aortic regurgitation. (Table 2).
Indication for endovascular 
intervention after previous
aortic surgery
Even after successful aortic root replacement, however, the 
dissected descending aorta remains a source of late compli-
cations in Marfan syndrome (von Kodolitsch et al 1994). 
The role of percutaneous stent-grafting for treatment of 
aortic pathologies in Marfan patients after aortic surgery is 
not established yet. In very small number of treated patients 
several groups could show the feasibility of stent-graft place-
ment with good short-term results (Nienaber et al 1999; Ince 
et al 2003; Wheatley et al 2006; Fattori et al 2006). The aim 
is to avoid an enlargement of the aorta or of the false lumen 
by sealing the proximal entry tear with a customized stent-
graft. Because of being a disease of the entire aorta, this 
procedure is just a therapeutic option to avoid a repeated 
aortic surgery. The reason for stent-graft placement against 
repeat aortic surgery in ﬁ  rst line is the mortality rate of 31% 
for repeated aortic surgery in Marfan patients (Carrel et al 
1993; Gott et al 1999, 2002).
Technique of endovascular 
stent-graft placement
Based on diagnosed measurements obtained during angiogra-
phy, transesophageal echography, or tomographic spiral CT 
or MRI, customized stent-grafts can be used to both scaffold 
up to 20 cm of dissected or dilatated aorta and cover major 
tears. The procedure is best performed in a hybrid laboratory 
with catheterization and imaging capabilities including digi-
tal angiography under general anesthesia and ventilation. The 
femoral artery is the most popular access-site and can usually 
accommodate a 24 F stent-graft system. The procedure will 
begin by injecting 5000 units of heparin. The femoral or 
distal iliac artery is surgically exposed. Using the Seldinger 
technique, a 260 cm, 0.89 mm (0.035 inch) stiff wire is 
placed over a pigtail catheter navigated with a soft wire in 
the true lumen under both ﬂ  uoroscopic and transesophageal 
ultrasound guidance. In complex cases with multiple reentries 
in the abdominal aorta, the embracement-technique with the 
use of 2 pig-tail catheters is useful. A pig-tail catheter, which 
Table 1 Characteristics of patients with and without Marfan 
syndrome in the International Registry of Aortic Dissection (IRAD) 
(Januzzi et al 2004)
 Marfan    Non-Marfan  p-value
 syndrome  syndrome 
Age (years)  35 ± 12  64 ± 13  <0.001
Systemic hypertension (%)  27  74  <0.001
Prior aortic aneurysm (%)  33  13  <0.001
Prior aortic dissection (%)  23  4  <0.001
Prior cardia surgery due 
  to aortic dissection (%)  27  8  <0.001
Prior aortic valve 
 replacement  (%)  19  4  <0.001
Sinus of Valsalva (cm)  5,05 ± 1,75 4,11  ± 0,96 0.006
Ascending aorta (cm)  5,29 ± 1,75 4,77  ± 1,31 0.09
Type A dissection (%)  76  62  0.04
Intramural hematoma  2  11  0.03Vascular Health and Risk Management 2008:4(1) 62
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has been installed in the true aortic lumen via the left brachial 
artery, picks up the femoral pig-tail catheter in the true 
lumen of the abdominal aorta and pulls it up into the aortic 
arch. This procedure ensures deﬁ  nite positioning of the stiff 
guide wire in the true lumen, which is essential for correct 
deployment of the stent-graft. Carefully advanced over the 
stiff wire, the launching of the stent-graft is performed with 
systolic blood pressure lowered to 50–60 mmHg by infusion 
sodium nitroprusside or by rapid right ventricular pacing to 
avoid misplacement. After deployment short inﬂ  ation of 
a latex balloon can improve apposition of the stent struts 
to the aortic wall, but only if proximal sealing of thoracic 
communications is incomplete. Both Doppler-ultrasound and 
contrast ﬂ  uoroscopy are instrumental for documenting the 
immediate result or initiating adjunctive maneuvers. After 
removing the sheath and guidewire the access sites can be 
closed in standard fashions.
Own experiences
There are only few data concerning stent-grafts to avoid 
repeat surgery for complicated persistent distal dissection 
after previous root replacement. In our institution, endo-
vascular reconstruction of a dissected Marfan aorta was 
subsequently attempted in seven consecutive cases with 
previous root replacement and in one case with isolated type 
B dissection. Transluminal placement of customized stent-
grafts was technically successful in 8 patients with Marfan 
syndrome with no 30 day or 1 year intervention-related 
mortality and without any signs of neurological complica-
tions (Figure 1). The follow-up ranges from 12 to 92 months 
(mean 63 ± 19). Mean stent-graft length was 151 ± 23 mm 
(range 90–180). Stent-graft procedures lasted a mean 132 ± 
34 minutes (range 97–236). False lumen thrombosis was seen 
in 6 of 8 patients. Complete abolition of the dissection and 
reconstruction of the entire dissected aorta was documented 
in 4 patients, and conversion to elective surgical repair in 3 
patients (22, 43, and 80 months after stent-graft implanta-
tion) due to enlargement of the false lumen. One patient died 
suddenly 12 months after endovascular repair.
Results from the literature
In the survey performed by Baril and colleagues (2006) 11 
of 1073 patients treated with endovascular stent-graft had an 
arteriopathy, 6 had Marfan syndrome, 3 had Takayasu’s Arte-
ritis, and 2 had a giant cell arteritis. Eight of the 11 patients 
had undergone previous aortic surgery. Technical success of 
Marfan-syndrome
Asymptomatic Symptomatic
DA 50–55 mm
DA > 55 mm 
DP > 5%/y 
Type-B-AD and 
DA < 55 mm
Type-B-AD and 
DA > 55 mm
Type-A-AD
Surgical repair
Conservative
(annual MRI, CT, TEE)  
Avoid extertion, beta-blocking-agents, PIE
family history of AD, AR
no risk factors
Annual MRI, CT, or TEE
No clinical symptoms
Clinical symptoms
Evaluation for repeat
surgery or EVSG 
Recurrence of AA or
AD in the treated or
entire aorta
Table 2 Flow chart for managment of Marfan patients with aortic disease
Abbreviations: PIE, prophylaxix of infective endocarditis; AD, aortic dissection; AR, aortic regurgitation; DP, diameter progression; EVSG, endovascular stent graft; AA, aortic 
aneurysm; DA, diameter of the aorta.Vascular Health and Risk Management 2008:4(1) 63
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the endovascular stent-graft placement was achieved in 92%. 
Early complications like wound infection and postoperative 
myocardial infarction was seen in 25%. There were no peri-
operative mortalities or immediate conversion to open sur-
gery (Baril et al 2006). Elective conversion to open surgery 
was performed in 3 of 6 patient in the follow-up (28 and 52 
month after EVSG) due to progression of the aortic disease 
in the entire aorta (n = 2) and due to rupture of the intercostal 
patch (n = 1). Similar satisfactory results with asymtomatic 
subjects and lacking signs for a dilatation in the treated aorta 
were reported in other case reports (Umana et al 2002; Fleck 
et al 2003; Dong et al 2005; Gaxotte et al 2006). Botta and 
colleagues (2006) treated succesfully a patient with unusual 
rapid evolution of type B aortic dissection following heart 
transplantation, which had an incidence of 40% for thoracic 
aortic dissection. The mortality rates of endovascular stent-
grafts for patients with acute aortic syndromes range from 
0% to 16% while the same patients treated surgically would 
have a risk in the range of 40% or perhaps even exceeding 
up to 70% if treated medically (Fann et al 1994).
Roux and colleagues (2002) treated a ﬁ  stula at the distal 
anastomisis after Bentall operation with endovascular stent 
graft with complete occlusion of the false aneurysm docu-
mented in the control comuted tomography in a 25-year-old 
Marfan patient. Another 42-year-old Marfan patient with 
type B dissection distal from the left subclavian artery up to 
the right iliac artery with no lower limb pulses and a poor 
perfusion of the left kidney was treated by Zaman and col-
leagues (2002) showing complete healing in the axial imaging 
performed one year later with no symptoms of lower limb 
paralysis nor left arm claudication (Table 3).
Discussion
Marfan syndrome is a generalized polymorphic inherited 
disease of connective tissue with large interfamilial and 
intrafamilial variability, complete penetrance, and autoso-
mal dominant transmission. It is relatively common, with 
an incidence of 1 per 10.000 with no difference according 
to gender, race, or ethnicity and is clinical characterized by 
abnormalities of the skeletal, ocular, and cardiovascular 
system (Pyeritz 1979).
Before delicate aortic surgery became available on a 
broader scale, the majority of patients with Marfan syndrome 
died prematurely of aortic rupture, often in their early adult-
hood (Gott et al 2002). In a survey performed by Murdoch and 
colleagues (1972) 50% of men affected by Marfan syndrome 
were dead by the age of 40 years. The success of current 
medical and surgical treatment of aortic disease in Marfan 
syndrome patients has substantially improved the average 
life expectancy, extending it up to 70 years (Finkbohner et al 
1995; Silvermann et al 1995). Umana and colleagues (2002) 
reported a trend to lower mortality risk: from 57% between 
1963 and 1969, to 27% between 1990 to 1999 for surgical 
patients. Introduction of both Bentall procedure (Bentall and 
DeBono 1968), composite graft conduits, and root recon-
struction eventually changed the bleak outlook for Marfan 
syndrome patients with aneurysm of the ascending aorta with 
improvement of the 10 year survival rate in prophylactic 
AB A
Figure 1 A. Sagittal view of a contrast enhanced computed tomography scan showing a native type B aortic dissection in a young Marfan syndrome patient; the 3 pictograms 
in axial view identify a small true lumen and a larger false. B. Gd-enhanced MR tomogram in sagittal orientation; Follow-up study one year after endovascular stent-graft place-
ment showing no resident false lumen and reconstruction of the dissected aorta as conﬁ  rmed on axial pictograms.Vascular Health and Risk Management 2008:4(1) 64
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aortic root replacement up to 97% compared with 34% in 
patients who did not undergo surgical intervention (Groenik 
et al 1999). A survey in 10 major Marfan centers reported a 
30-day mortality rate of 1.5% for patients undergoing elective 
repair of aortic root aneurysms; and 11.7% among patients 
requiring emergent surgery (Gott et al 1999). Even after 
successful aortic root replacement, however, the dissected 
descending aorta remains a source of late complications in 
Marfan syndrome (von Kodolitsch et al 1999).
In contrast to excellent surgical results of elective root 
replacement, both early and long-term results of repeat sur-
gery for the descending aorta, which is required subsequently 
in 10% to 27% (von Kodolitsch et al 1998b), remain poor 
and had a mortality rate up to 31% (Silvermann et al 1995; 
Gott et al 1999, 2002; DeOliveira et al 2003). In the report 
of DeOliveira and colleagues (2003) including 4 Marfan 
patients with previous aortic root surgery requiring replace-
ment of both the thoracic and abdominal aorta for expansion 
or imminent rupture of the false lumen 1 patient died, a 
second became paraplegic, and only 2 fared well. In a recent 
study by Alexiou and colleagues (2001) 3 of 7 patients with 
Marfan syndrome and late postoperative aortic complications 
underwent resurgery of the descending aorta after previous 
aortic root replacement with a 33% mortality. A larger survey 
reported 63 of 653 Marfan syndrome patients with previous 
aortic root replacement to require late aortic surgery for pro-
gressive disease; only 46 patients were alive at the time of last 
follow-up (Dong et al 2005). More than half of these second 
interventions take place without direct anatomical relation 
with the preoperated aortic segment. In 40% of patients, local 
complications of the preoperated aorta in the area of the aorta 
ascendens or the aortic arch lead to an individualized second 
intervention (von Kodolitsch et al 1998b).
The postoperative mortality rate is determined by late 
aortic dissection in 33% and progressive heart failure in 
35% of the Marfan patients with previously aortic surgery. 
Five and 15 year survival rate were 71% to 88% and 71% 
respectively (von Kodolitsch et al 1998b).
In contrast to the increased risk of repeat aortic surgery 
endovascular stent-graft repair could be a feasible alterna-
tive to open surgery in selected cases. To date there are only 
limited experiences with stent-grafts in Marfan patients 
(Table 3).
This limited data demonstrate not only technical feasibil-
ity, but also some therapeutic potential of endovascular stent-
graft treatment in Marfan syndrome with distal dissection 
after complex aortic root repair or acute aortic syndrome. The 
technical execution of endovascular stent-graft deployment 
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was safe, since peri- and post-interventional outcomes were 
favorable. Preservation of the integrity of the aorta, rather 
than surgical resection, has previously proven to avoid neu-
rological events and interference with spinal artery supply 
(Rapezzi et al 2001; Ince et al 2003). None of our patients 
had neurological or vascular events, although the risk of 
paraplegia with elective surgery of the descending aorta is 
estimated at 8%; such risk ﬁ  gures pertain to centers with 
special experience in aortic surgery, and to patients without 
any previous surgical repair of the aorta (Eleftriades 2002). 
Although the endovascular strategy was employed in rela-
tively few patients and observational in nature, it revealed 
a feasible and relatively safe nonsurgical alternative to treat 
descending aortic dissection in Marfan patients after aortic 
surgery. Regardless of feasibility, however, conversion to 
surgery after stent-graft placement underlines that endovas-
cular stent-grafting should be considered a bridging rather 
than curative procedure, which was also conﬁ  rmed by the 
data of Baril and colleagues (2006). They could demon-
strate that 2 of 6 initially successful treated patients had to 
be converted to surgery due to abnormalities in the entire 
aorta. Furthermore, with death of one patient (12 month after 
stent-graft implantation) who suffered from complex aortic 
pathology both close surveillance and repeat imaging of the 
aorta appear mandatory to detect silent postinterventional 
complications eventually requiring surgical repair.
Although conceptually promising – considering sobering 
results of surgical repair (Svennson et al 2004) – adjunctive 
management by stent-graft placement in distally extending 
dissection lacks the support of long-term follow-up data. 
Nevertheless, over several years of follow-up after stent-graft 
placement for the treatment of both thoracic and abdominal 
aneurysms, late adverse effects were infrequent and may jus-
tify “bridging” stent-grafts even in relatively young patients 
with Marfan syndrome after aortic root surgery (Nienaber 
et al 1999a, 1999b; Ince et al 2003, 2005; Svennson et al 
2004) in the attempt to avoid the risks of (emergent) repeat 
surgery.
In summary, due to the lack of long-term follow-up expe-
rience and small number of cases published, endovascular 
stent-graft treatment may emerge in the future as a feasible 
therapeutic option for Marfan patients with late distal com-
plications following aortic surgery, but clear evidence is 
still missing.
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